May 21, 2018
By Reuters Staff
(Reuters) - Nabriva Therapeutics Plc said on Monday its antibiotic to treat adults with community-acquired bacterial pneumonia met the main goal of a second late-stage study, putting the company on track to file for the drug's approval in the fourth quarter of 2018.
The study showed that antibiotic drug lefamulin is as potent as commonly used treatments. But since it belongs to a new class of medicine, it could prove to be effective in combating increasingly resistant "superbugs."
Lefamulin is the company's lead experimental treatment and belongs to a group of drugs called pleuromutilin antibiotics, which inhibit growth of a protein that is required for bacteria to grow.
"We are one step closer to potentially making a much-needed new class of antibiotics available to patients and health care providers," Chief Medical Officer Jennifer Schranz said in a statement.
SunTrust analysts, in a note published earlier this month, estimated worldwide peak sales of $684 million for lefamulin.
Current options to treat community-acquired bacterial pneumonia include fluoroquinolones, which are declining in use due to rising resistance, Wedbush analyst Robert Driscoll said in a note on Wednesday.
At least 2 million become infected with antibiotic-resistant bacteria and at least 23,000 die each year in the United States due to these infections, according to the U.S. Centers for Disease Control and Prevention.
Lefamulin succeeded in another late-stage study in community-acquired bacterial pneumonia patients last September.
(c) Copyright Thomson Reuters 2018. Click For Restrictions - https://agency.reuters.com/en/copyright.html
For more Pharmacy Learning Network articles, visit the homepage
To learn about Pharmacy Learning Network Live meetings, click here